“Teva Pharmaceuticals has again defeated arguments that its generic version of the anti-overdose nasal spray Narcan violates patents on the drug, persuading a U.S. appeals court on Thursday to reject a lawsuit by Narcan maker Adapt Pharma.
The U.S. Court of Appeals for the Federal Circuit upheld a New Jersey court’s 2020 finding that the patents were invalid because earlier publications disclosed the same innovations.”
The Sterne, Kessler, Goldstein & Fox team representing Teva was led by J.C. Rozendaal, director and chair of the firm’s Trial & Appellate Group and includes fellow Directors: Paul Ainsworth, Michael Joffre, Adam LaRock, William Milliken, and Chandrika Vira.
To read the full article, please click the link below.
Read
Full Article
Receive insights from the most respected practitioners of IP law, straight to your inbox.
Subscribe for Updates